VEPESID Side Effects

5884092-9 | Tumour Lysis Syndrome
on Sep 10, 2008 Male patient from JAPAN , 47 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: tumour lysis syndrome. Vepesid dosage: . During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

5824046-1 | Back Pain
Patient was taking Vepesid (View Usage). Patient had the following side effects: back pain (What is back pain?) on Jul 24, 2008 from BULGARIA Additional patient health information: Male patient , 72 years of age, was diagnosed with gastric cancer and. Vepesid dosage: .

5815713-4 | Back Pain
Adverse event was reported on Jul 17, 2008 by a Male patient taking Vepesid (View Usage) (Dosage: Also Received On 30-jun-2008.) was diagnosed with gastric cancer and. Location: BULGARIA , 72 years of age, After Vepesid was administered, patient had the following side effects: back pain (What is back pain?).

5805389-4 | Prostatic Abscess, Pyrexia, White Blood Cell Count Decreased
on Jul 07, 2008 Male patient from JAPAN , 22 years of age, was diagnosed with testicular cancer metastatic, germ cell cancer and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: prostatic abscess, pyrexia, white blood cell count decreased. Vepesid dosage: Administered On Days 1 To 5. During the same period patient was treated with BRIPLATIN (Administered On Days 1 To 5) (View Briplatin Review and Briplatin Label ), BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ).


5799457-3 | Hyponatraemia, Leukopenia, Neutropenia
on Jun 25, 2008 Male patient from JAPAN , 33 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Vepesid (View Usage). Patient had the following side effects: hyponatraemia, leukopenia, neutropenia. Vepesid dosage: On Days 2-4.. During the same period patient was treated with IFOSFAMIDE (1.5 Gram Per M2 On Days 2-4.) (View Ifosfamide Review and Ifosfamide Label ), METHOTREXATE (Per M2 Over 6 Hours On Day1.) (View Methotrexate Review and Methotrexate Label ), ELSPAR (Df- Units/m2. On Days 8,10,12,14,16,18 And 20.) (View Elspar Review and Elspar Label ), DEXAMETHASONE TAB (40mg Per Body On Days 2 - 4.) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), LEUCOVORIN CALCIUM (View Leucovorin Calcium Review and Leucovorin Calcium Label ), MESNA (At 4 And 8 Hours.) (View Mesna Review and Mesna Label ).

5799455-X | Activated Partial Thromboplastin Time Prolonged, Hyperglycaemia, Hyponatraemia, Leukopenia, Nausea, Neutropenia
Patient was taking Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: activated partial thromboplastin time prolonged, hyperglycaemia, hyponatraemia, leukopenia, nausea (What is nausea?), neutropenia on Jun 25, 2008 from JAPAN Additional patient health information: Male patient , 57 years of age, was diagnosed with lymphoma (What is lymphoma?) and. Vepesid dosage: On Days 2-4.. During the same period patient was treated with IFOSFAMIDE (1.5 Gram Per M2 On Days 2-4.) (View Ifosfamide Review and Ifosfamide Label ), METHOTREXATE (Per M2 Over 6 Hours On Day1.) (View Methotrexate Review and Methotrexate Label ), ELSPAR (Df- Units/m2. On Days 8,10,12,14,16,18 And 20.) (View Elspar Review and Elspar Label ), DEXAMETHASONE TAB (40mg Per Body On Days 2 - 4.) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), LEUCOVORIN CALCIUM (View Leucovorin Calcium Review and Leucovorin Calcium Label ), MESNA (At 4 And 8 Hours.) (View Mesna Review and Mesna Label ).

5799454-8 | Anaemia, Hypocoagulable State, Pancytopenia
Adverse event was reported on Jun 25, 2008 by a Male patient taking Vepesid (View Usage) (Dosage: On Days 2-4.) was diagnosed with lymphoma (What is lymphoma?), leukaemia and. Location: JAPAN , 28 years of age, Patient experienced the following unwanted or unexpected effects: anaemia, hypocoagulable state, pancytopenia. During the same period patient was treated with IFOSFAMIDE (1.5 Gram Per M2 On Days 2-4.) (View Ifosfamide Review and Ifosfamide Label ), METHOTREXATE (Per M2 Over 6 Hours On Day1) (View Methotrexate Review and Methotrexate Label ), ELSPAR (Df- Units/m2. On Days 8,10,12,14,16,18 And 20.) (View Elspar Review and Elspar Label ), DEXAMETHASONE TAB (40mg Per Body On Days 2 - 4.) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), LEUCOVORIN CALCIUM (View Leucovorin Calcium Review and Leucovorin Calcium Label ), MESNA (At 4 And 8 Hours.) (View Mesna Review and Mesna Label ).

5799453-6 | Anaemia, Hyponatraemia, Leukopenia, Neutropenia
on Jun 25, 2008 Male patient from JAPAN , 39 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Vepesid (View Usage). Patient had the following side effects: anaemia, hyponatraemia, leukopenia, neutropenia. Vepesid dosage: On Days 2-4.. During the same period patient was treated with IFOSFAMIDE (1.5 Gram Per M2 On Days 2-4.) (View Ifosfamide Review and Ifosfamide Label ), METHOTREXATE (Per M2 Over 6 Hours On Day1.) (View Methotrexate Review and Methotrexate Label ), ELSPAR (Df- Units/m2. On Days 8,10,12,14,16,18 And 20.) (View Elspar Review and Elspar Label ), DEXAMETHASONE TAB (40mg Per Body On Days 2 - 4.) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), LEUCOVORIN CALCIUM (View Leucovorin Calcium Review and Leucovorin Calcium Label ), MESNA (At 4 And 8 Hours.) (View Mesna Review and Mesna Label ).

5799452-4 | Alanine Aminotransferase Increased, Anaemia, Aspartate Aminotransferase Increased, Febrile Neutropenia, Leukopenia, Sepsis
on Jun 25, 2008 Male patient from JAPAN , 63 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: alanine aminotransferase increased, anaemia, aspartate aminotransferase increased, febrile neutropenia, leukopenia, sepsis (What is sepsis?). Vepesid dosage: On Days 2-4.. During the same period patient was treated with IFOSFAMIDE (1.5 Gram Per M2 On Days 2-4.) (View Ifosfamide Review and Ifosfamide Label ), METHOTREXATE (Per M2 Over 6 Hours On Day1.) (View Methotrexate Review and Methotrexate Label ), ELSPAR (Df- Units/m2. On Days 8,10,12,14,16,18 And 20.) (View Elspar Review and Elspar Label ), DEXAMETHASONE TAB (40mg Per Body On Days 2 - 4.) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), LEUCOVORIN CALCIUM (View Leucovorin Calcium Review and Leucovorin Calcium Label ), MESNA (At 4 And 8 Hours.) (View Mesna Review and Mesna Label ).

5750571-8 | Renal Failure Acute
Patient was taking Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: renal failure acute on May 23, 2008 from JAPAN Additional patient health information: Female patient , child 4 years of age, was diagnosed with acute lymphocytic leukaemia and. Vepesid dosage: Initial Dose Was 100mg/m2 1 Per 1 Day, Intravenous Drip, 09-may-2008 To 09-may-2008..

5734963-9 | Interstitial Lung Disease
Adverse event was reported on May 07, 2008 by a Female patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with lung neoplasm malignant and. Location: JAPAN , 64 years of age, Patient had the following side effects: interstitial lung disease. During the same period patient was treated with PARAPLATIN (Initiated On Day 1.) (View Paraplatin Review and Paraplatin Label ).

5694464-3 | Acute Lymphocytic Leukaemia
on Apr 01, 2008 Male patient from JAPAN , 17 years of age, was diagnosed with ewing's sarcoma and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: acute lymphocytic leukaemia. Vepesid dosage: . During the same period patient was treated with ONCOVIN (View Oncovin Review and Oncovin Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ENDOXAN (View Endoxan Review and Endoxan Label ), IFOMIDE (View Ifomide Review and Ifomide Label ).

5668980-4 | Blast Cell Crisis
on Mar 12, 2008 Male patient from JAPAN , 17 years of age, was diagnosed with ewing's sarcoma and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: blast cell crisis. Vepesid dosage: . During the same period patient was treated with ONCOVIN (View Oncovin Review and Oncovin Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ENDOXAN (View Endoxan Review and Endoxan Label ), IFOMIDE (View Ifomide Review and Ifomide Label ).

5654578-0 | Tumour Haemorrhage
Patient was taking Vepesid (View Usage). Patient had the following side effects: tumour haemorrhage on Mar 03, 2008 from JAPAN Additional patient health information: Male patient , 27 years of age, was diagnosed with pseudosarcoma and. Vepesid dosage: . During the same period patient was treated with ONCOVIN (View Oncovin Review and Oncovin Label ), IFOMIDE (View Ifomide Review and Ifomide Label ). Patient was hospitalized.

5564366-1 | Convulsion, Nephropathy
Adverse event was reported on Dec 06, 2007 by a Female patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with optic nerve glioma and. Location: JAPAN , child 7 years of age, After Vepesid was administered, patient had the following side effects: convulsion, nephropathy. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), RANDA (View Randa Review and Randa Label ).

5557291-3 | Hyponatraemia, Subdural Haematoma
on Dec 06, 2007 Female patient from JAPAN , child 6 years of age, was diagnosed with optic nerve glioma and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: hyponatraemia, subdural haematoma. Vepesid dosage: 5 Courses Completed.. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), RANDA (View Randa Review and Randa Label ).

5541507-3 | Acute Myeloid Leukaemia, Pneumonia
on Nov 29, 2007 Female patient from JAPAN , 28 years of age, was diagnosed with acute lymphocytic leukaemia, bone marrow conditioning regimen and was treated with Vepesid (View Usage). Patient had the following side effects: acute myeloid leukaemia, pneumonia (What is pneumonia?). Vepesid dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), CYLOCIDE (View Cylocide Review and Cylocide Label ), LEUNASE (View Leunase Review and Leunase Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ).

5506114-7 | Acute Myeloid Leukaemia, Pneumonia
Patient was taking Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: acute myeloid leukaemia, pneumonia (What is pneumonia?) on Oct 24, 2007 from UNITED STATES Additional patient health information: Female patient , 28 years of age, was diagnosed with acute lymphocytic leukaemia, bone marrow conditioning regimen and. Vepesid dosage: . During the same period patient was treated with ENDOXAN (1650 Mg On 07-mar-2006 And From 25-aug-05 -60mg/kg) (View Endoxan Review and Endoxan Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), CYLOCIDE (2.7gx2/day From 17/apr/2006-20/apr/2006) (View Cylocide Review and Cylocide Label ), LEUNASE (View Leunase Review and Leunase Label ), ADRIACIN (View Adriacin Review and Adriacin Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ).

5506108-1 | Chronic Myelomonocytic Leukaemia
Adverse event was reported on Oct 31, 2007 by a Male patient taking Vepesid (View Usage) (Dosage: ) . Location: JAPAN , 58 years of age, Patient experienced the following unwanted or unexpected effects: chronic myelomonocytic leukaemia. During the same period patient was treated with NOVANTRONE (View Novantrone Review and Novantrone Label ), DAUNOMYCIN (View Daunomycin Review and Daunomycin Label ), ACLACINON (View Aclacinon Review and Aclacinon Label ).

5500769-9 | Acute Myeloid Leukaemia, Pneumonia
on Oct 24, 2007 Female patient from JAPAN , 28 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Vepesid (View Usage). Patient had the following side effects: acute myeloid leukaemia, pneumonia (What is pneumonia?). Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), CYLOCIDE (Cytorabine 2.7gx2 Per Day Was Given From 17-apr-2006 To 20-apr-2006 For 4 Days.) (View Cylocide Review and Cylocide Label ), LEUNASE (View Leunase Review and Leunase Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ).

5496190-2 | Acute Respiratory Distress Syndrome, Interstitial Lung Disease
on Oct 19, 2007 Female patient from JAPAN , 74 years of age, was diagnosed with ovarian cancer and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: acute respiratory distress syndrome, interstitial lung disease. Vepesid dosage: . Patient was hospitalized.

5491748-9 | Acute Myeloid Leukaemia, Pneumonia
Patient was taking Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, pneumonia (What is pneumonia?) on Oct 15, 2007 from JAPAN Additional patient health information: Female patient , 28 years of age, was diagnosed with acute lymphocytic leukaemia and. Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), DAUNOMYCIN (View Daunomycin Review and Daunomycin Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5486941-5 | Lung Disorder
Adverse event was reported on Oct 12, 2007 by a Female patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with ovarian cancer and. Location: JAPAN , 74 years of age, Patient had the following side effects: lung disorder. Patient was hospitalized.

5485373-3 | Interstitial Lung Disease, Malignant Neoplasm Progression, Neoplasm Recurrence
on Oct 09, 2007 Female patient from JAPAN , 58 years of age, was diagnosed with hepatic mass and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: interstitial lung disease, malignant neoplasm progression, neoplasm recurrence. Vepesid dosage: . During the same period patient was treated with ADRIAMYCIN RDF (View Adriamycin Rdf Review and Adriamycin Rdf Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), RANDA (View Randa Review and Randa Label ).

5464215-6 | Bronchial Obstruction, Dyspnoea, Erythema, Feeling Hot, Oxygen Saturation Decreased, Sinus Tachycardia
on Sep 18, 2007 Female patient from GERMANY , 60 years of age, weighting 83.78 lb, was diagnosed with bronchial carcinoma and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: bronchial obstruction, dyspnoea, erythema, feeling hot, oxygen saturation decreased, sinus tachycardia. Vepesid dosage: .

5456479-X | Dysphagia, Swelling Face, Swollen Tongue
Patient was taking Vepesid (View Usage). Patient had the following side effects: dysphagia, swelling face, swollen tongue on Sep 14, 2007 from UNITED KINGDOM Additional patient health information: Male patient , 66 years of age, weighting 224.9 lb, was diagnosed with vomiting and. Vepesid dosage: Cycle2:on 22aug 2007 120mg/m2(total Dose 240mg). During the same period patient was treated with PARAPLATIN (Auc=5 On Day 1.) (View Paraplatin Review and Paraplatin Label ), METOCLOPRAMIDE (Also On 23-aug-2007 To 25-aug-2007.) (View Metoclopramide Review and Metoclopramide Label ), DEXAMETHASONE 0.5MG TAB (On Day 1 Of The Cycle) (View Dexamethasone 0.5mg Tab Review and Dexamethasone 0.5mg Tab Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ). Patient was hospitalized.

5446065-X | Swelling Face, Swollen Tongue
Adverse event was reported on Sep 05, 2007 by a Male patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with vomiting and. Location: UNITED KINGDOM , 66 years of age, After Vepesid was administered, patient had the following side effects: swelling face, swollen tongue. During the same period patient was treated with PARAPLATIN (Auc=5 On Day 1.) (View Paraplatin Review and Paraplatin Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ), DEXAMETHASONE 0.5MG TAB (On Day 1 Of The Cycle) (View Dexamethasone 0.5mg Tab Review and Dexamethasone 0.5mg Tab Label ). Patient was hospitalized.

5425982-0 | Circulatory Collapse, Pancytopenia, Pyrexia, Renal Failure Acute
on Aug 24, 2007 Female patient from JAPAN , 42 years of age, weighting 130.1 lb, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: circulatory collapse, pancytopenia, pyrexia, renal failure acute. Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), BLEOMYCIN (View Bleomycin Review and Bleomycin Label ), NATULAN (View Natulan Review and Natulan Label ). Patient was hospitalized.

5424811-9 | Syncope
on Aug 21, 2007 Male patient from ITALY , 59 years of age, was treated with Vepesid (View Usage). Patient had the following side effects: syncope. Vepesid dosage: .

5411952-5 | Circulatory Collapse, Pancytopenia, Pyrexia, Renal Failure Acute
Patient was taking Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: circulatory collapse, pancytopenia, pyrexia, renal failure acute on Aug 09, 2007 from GERMANY Additional patient health information: Female patient , 42 years of age, weighting 130.1 lb, . Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), BLEOMYCIN (View Bleomycin Review and Bleomycin Label ), NATULAN (View Natulan Review and Natulan Label ). Patient was hospitalized.

5399609-0 | Bone Marrow Failure, Hydrocephalus, Inappropriate Antidiuretic Hormone Secretion, Intestinal Obstruction
Adverse event was reported on Jul 24, 2007 by a Male patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with ependymoma, catheter sepsis and. Location: JAPAN , child 2 years of age, Patient experienced the following unwanted or unexpected effects: bone marrow failure, hydrocephalus (What is hydrocephalus?), inappropriate antidiuretic hormone secretion, intestinal obstruction. During the same period patient was treated with BRIPLATIN (View Briplatin Review and Briplatin Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ITRACONAZOLE (View Itraconazole Review and Itraconazole Label ).

5395173-0 | Acute Hepatic Failure, Haematemesis, Hepatorenal Syndrome, Hypotension, Nausea, Tachycardia, Urine Output Decreased
on Jul 23, 2007 Male patient from PORTUGAL , 77 years of age, weighting 176.4 lb, was diagnosed with chronic myelomonocytic leukaemia, hypertension, hypercholesterolaemia, hyperuricaemia, benign prostatic hyperplasia and was treated with Vepesid (View Usage). Patient had the following side effects: acute hepatic failure, haematemesis, hepatorenal syndrome, hypotension, nausea (What is nausea?), tachycardia, urine output decreased. Vepesid dosage: . During the same period patient was treated with LOSARTAN POTASSIUM (View Losartan Potassium Review and Losartan Potassium Label ), ATORVASTATIN CALCIUM (View Atorvastatin Calcium Review and Atorvastatin Calcium Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), SERENOA REPENS (View Serenoa Repens Review and Serenoa Repens Label ), DARBEPOETIN ALFA (View Darbepoetin Alfa Review and Darbepoetin Alfa Label ).

5369374-1 | Tumour Lysis Syndrome
on Jun 21, 2007 Male patient from UNITED STATES , 21 years of age, was diagnosed with burkitt's lymphoma and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: tumour lysis syndrome. Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), IFOMIDE (View Ifomide Review and Ifomide Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5350481-4 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Bacterial Sepsis, Blood Creatine Phosphokinase Increased, Blood Creatinine Increased, Blood Lactate Dehydrogenase Increased, Blood Potassium Decreased, Bone Marrow Failure, C-reactive Protein Increased
Patient was taking Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, bacterial sepsis, blood creatine phosphokinase increased, blood creatinine increased, blood lactate dehydrogenase increased, blood potassium decreased, bone marrow failure, c-reactive protein increased on Jun 05, 2007 from FRANCE Additional patient health information: Male patient , 50 years of age, was diagnosed with acute lymphocytic leukaemia and. Vepesid dosage: 150 Mg Daily. During the same period patient was treated with PURINETHOL (50 Mg, Bid) (View Purinethol Review and Purinethol Label ), DEXAMETHASONE 0.5MG TAB (20 Mg, Bid) (View Dexamethasone 0.5mg Tab Review and Dexamethasone 0.5mg Tab Label ), GLEEVEC (400 Mg, Bid) (View Gleevec Review and Gleevec Label ). Patient was hospitalized.

5331111-4 | Tumour Lysis Syndrome
Adverse event was reported on May 15, 2007 by a Male patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with burkitt's lymphoma and. Location: JAPAN , 21 years of age, Patient had the following side effects: tumour lysis syndrome. During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), IFOMIDE (View Ifomide Review and Ifomide Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ARA C (View Ara-c Review and Ara-c Label ).

5326104-7 | Acute Hepatic Failure, Haematemesis, Hepatorenal Syndrome, Hypotension, Nausea, Tachycardia, Urine Output Decreased
on May 14, 2007 Male patient from PORTUGAL , 77 years of age, weighting 176.4 lb, was diagnosed with chronic myelomonocytic leukaemia, hypertension, hypercholesterolaemia, hyperuricaemia, benign prostatic hyperplasia and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: acute hepatic failure, haematemesis, hepatorenal syndrome, hypotension, nausea (What is nausea?), tachycardia, urine output decreased. Vepesid dosage: . During the same period patient was treated with LOSARTAN POTASSIUM (View Losartan Potassium Review and Losartan Potassium Label ), ATORVASTATIN CALCIUM (View Atorvastatin Calcium Review and Atorvastatin Calcium Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), SERENOA REPENS (View Serenoa Repens Review and Serenoa Repens Label ), DARBEPOETIN ALFA (View Darbepoetin Alfa Review and Darbepoetin Alfa Label ).

5318950-0 | Malignant Neoplasm Progression
on May 07, 2007 Female patient from UNITED STATES , 64 years of age, was diagnosed with lung cancer metastatic and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: malignant neoplasm progression. Vepesid dosage: . During the same period patient was treated with DEXAMETHASONE 0.5MG TAB (View Dexamethasone 0.5mg Tab Review and Dexamethasone 0.5mg Tab Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), OXYCODONE HCL (View Oxycodone Hcl Review and Oxycodone Hcl Label ).

5306125-0 | Lymphoma, Malignant Neoplasm Progression
Patient was taking Vepesid (View Usage). Patient had the following side effects: lymphoma (What is lymphoma?), malignant neoplasm progression on Apr 23, 2007 from JAPAN Additional patient health information: Male patient , 77 years of age, was diagnosed with prostate cancer (What is prostate cancer?) and. Vepesid dosage: . During the same period patient was treated with ESTRACYT (View Estracyt Review and Estracyt Label ), SELBEX (View Selbex Review and Selbex Label ), BUP 4 (View Bup-4 Review and Bup-4 Label ).

5301959-0 | Lymphoma, Malignant Neoplasm Progression
Adverse event was reported on Apr 16, 2007 by a Male patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with prostate cancer (What is prostate cancer?) and. Location: JAPAN , 77 years of age, After Vepesid was administered, patient had the following side effects: lymphoma (What is lymphoma?), malignant neoplasm progression. During the same period patient was treated with ESTRACYT (View Estracyt Review and Estracyt Label ), SELBEX (View Selbex Review and Selbex Label ), BUP 4 (View Bup-4 Review and Bup-4 Label ).

5301659-7 | Interstitial Lung Disease, Malignant Neoplasm Progression, White Blood Cell Count Decreased
on Apr 16, 2007 Male patient from JAPAN , 83 years of age, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: interstitial lung disease, malignant neoplasm progression, white blood cell count decreased. Vepesid dosage: . During the same period patient was treated with ESTRACYT (View Estracyt Review and Estracyt Label ), ALOTEC (View Alotec Review and Alotec Label ), GASTER (View Gaster Review and Gaster Label ), GRAN (View Gran Review and Gran Label ), TIENAM (View Tienam Review and Tienam Label ), DIFLUCAN (View Diflucan Review and Diflucan Label ), VENOGLOBULIN (View Venoglobulin Review and Venoglobulin Label ). Patient was hospitalized.

5276820-0 | Interstitial Lung Disease, White Blood Cell Count Decreased
on Mar 20, 2007 Male patient from JAPAN , 83 years of age, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Vepesid (View Usage). Patient had the following side effects: interstitial lung disease, white blood cell count decreased. Vepesid dosage: . During the same period patient was treated with ESTRACYT (View Estracyt Review and Estracyt Label ), ALOTEC (View Alotec Review and Alotec Label ), GASTER (View Gaster Review and Gaster Label ), GRAN (View Gran Review and Gran Label ), TIENAM (View Tienam Review and Tienam Label ), DIFLUCAN (View Diflucan Review and Diflucan Label ), VENOGLOBULIN (View Venoglobulin Review and Venoglobulin Label ). Patient was hospitalized.

5254978-7 | Interstitial Lung Disease
Patient was taking Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: interstitial lung disease on Mar 01, 2007 from JAPAN Additional patient health information: Female patient , 31 years of age, was diagnosed with choriocarcinoma and. Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), DACTINOMYCIN (View Dactinomycin Review and Dactinomycin Label ), ONCOVIN (View Oncovin Review and Oncovin Label ). Patient was hospitalized.

5246740-6 | Deep Vein Thrombosis, Vena Cava Thrombosis
Adverse event was reported on Feb 23, 2007 by a Male patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with testis cancer and. Location: JAPAN , 28 years of age, Patient experienced the following unwanted or unexpected effects: deep vein thrombosis (What is deep vein thrombosis?), vena cava thrombosis. During the same period patient was treated with BLEOMYCIN (View Bleomycin Review and Bleomycin Label ), RANDA (View Randa Review and Randa Label ), SAXIZON (View Saxizon Review and Saxizon Label ), SEROTONE (View Serotone Review and Serotone Label ).

5242588-7 | Interstitial Lung Disease
on Feb 09, 2007 Female patient from JAPAN , 31 years of age, was diagnosed with choriocarcinoma and was treated with Vepesid (View Usage). Patient had the following side effects: interstitial lung disease. Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), DACTINOMYCIN (View Dactinomycin Review and Dactinomycin Label ), ONCOVIN (View Oncovin Review and Oncovin Label ). Patient was hospitalized.

5215817-3 | Cystitis Haemorrhagic
on Jan 17, 2007 Male patient from JAPAN , 16 years of age, was diagnosed with acute lymphocytic leukaemia, bone marrow conditioning regimen and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: cystitis haemorrhagic. Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ). Patient was hospitalized.

5198394-5 | Venoocclusive Liver Disease
Patient was taking Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: venoocclusive liver disease on Dec 26, 2006 from JAPAN Additional patient health information: Male patient , child 1 years of age, was diagnosed with neuroblastoma (What is neuroblastoma?) and. Vepesid dosage: . During the same period patient was treated with PARAPLATIN (View Paraplatin Review and Paraplatin Label ), RANDA (View Randa Review and Randa Label ), ENDOXAN (View Endoxan Review and Endoxan Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), PIRARUBICIN (View Pirarubicin Review and Pirarubicin Label ), ALKERAN (View Alkeran Review and Alkeran Label ). Patient was hospitalized.

5188013-6 | Haemoglobin Decreased, Platelet Count Decreased, Venoocclusive Liver Disease, White Blood Cell Count Decreased
Adverse event was reported on Jul 20, 2006 by a Female patient taking Vepesid (View Usage) (Dosage: ) was diagnosed with lymphoma (What is lymphoma?), infection prophylaxis and. Location: JAPAN , 62 years of age, Patient had the following side effects: haemoglobin decreased, platelet count decreased, venoocclusive liver disease, white blood cell count decreased. During the same period patient was treated with CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CISPLATIN MARUKO (View Cisplatin Maruko Review and Cisplatin Maruko Label ), CYMERIN (View Cymerin Review and Cymerin Label ), CYLOCIDE (View Cylocide Review and Cylocide Label ), BACTRIM (View Bactrim Review and Bactrim Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), RITUXAN (View Rituxan Review and Rituxan Label ). Patient was hospitalized.

5177175-2 | Lymphoma, Treatment Related Secondary Malignancy
on Nov 25, 2005 Female patient from UNITED STATES , child 10 years of age, was diagnosed with rhabdomyosarcoma and was treated with Vepesid (View Usage). After Vepesid was administered, patient had the following side effects: lymphoma (What is lymphoma?), treatment related secondary malignancy. Vepesid dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), IFOMIDE (View Ifomide Review and Ifomide Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), THERARUBICIN (View Therarubicin Review and Therarubicin Label ), DACTINOMYCIN (View Dactinomycin Review and Dactinomycin Label ), LASTET (View Lastet Review and Lastet Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ).

5168333-1 | Akinesia, Anaemia, Cardiac Murmur, Ejection Fraction Decreased, Escherichia Urinary Tract Infection, Heart Rate Increased, Hypoxia, Interstitial Lung Disease, Lung Infection
on Nov 22, 2006 Male patient from FRANCE , weighting 172.0 lb, was diagnosed with germ cell cancer and was treated with Vepesid (View Usage). Patient experienced the following unwanted or unexpected effects: akinesia, anaemia, cardiac murmur, ejection fraction decreased, escherichia urinary tract infection, heart rate increased, hypoxia, interstitial lung disease, lung infection. Vepesid dosage: 100 Mg/m2 For 5 Days Q3w. During the same period patient was treated with PAXENE (View Paxene Review and Paxene Label ), HOLOXAN (2 G/m2 On D10, 12, 14 Q3w) (View Holoxan Review and Holoxan Label ), BLEOMYCIN (30 Mg/day On D1,8 And 15 Q3w Or 25 Unit/day As Continuous Infusion From D10 To 14) (View Bleomycin Review and Bleomycin Label ), CISPLATIN (20 Mg/m2 For 5 Days Q3w, Or 100 Mg/m2 On D1 Q3w) (View Cisplatin Review and Cisplatin Label ), OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ). Patient was hospitalized.

5166708-8 | Gastrointestinal Haemorrhage, Haemoglobin Decreased
Patient was taking Vepesid (View Usage). Patient had the following side effects: gastrointestinal haemorrhage, haemoglobin decreased on Jul 20, 2006 from JAPAN Additional patient health information: Male patient , 77 years of age, was diagnosed with lymphoma (What is lymphoma?) and. Vepesid dosage: . During the same period patient was treated with CISPLATIN MARUKO (View Cisplatin Maruko Review and Cisplatin Maruko Label ), MEYLON (View Meylon Review and Meylon Label ), KYTRIL (View Kytril Review and Kytril Label ), LASIX (View Lasix Review and Lasix Label ), RITUXAN (View Rituxan Review and Rituxan Label ), PREDOPA (View Predopa Review and Predopa Label ), PRIMPERAN TAB (View Primperan Tab Review and Primperan Tab Label ), GRAN (View Gran Review and Gran Label ). Patient was hospitalized.